Kun-huei Yeh

Dawan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

Conversion-intent definitive liver-directed therapy improves survival in liver-predominant metastatic colorectal cancer.

Conversion-intent definitive liver-directed therapy improves survival in liver-predominant metastatic colorectal cancer.

Journal: American journal of cancer research

Published: February 11, 2026

Epigenetic reprogramming of hexokinase domain containing 1 (HKDC1) promotes proliferation in colorectal cancer.

Epigenetic reprogramming of hexokinase domain containing 1 (HKDC1) promotes proliferation in colorectal cancer.

Journal: American journal of cancer research

Published: January 10, 2026

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: September 27, 2025

FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features.

FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features.

Journal: Blood

Published: September 03, 2025

Incorporating nivolumab with preceded gemcitabine and S-1 chemotherapy for patients of metastatic pancreatic cancer: a pilot study.

Incorporating nivolumab with preceded gemcitabine and S-1 chemotherapy for patients of metastatic pancreatic cancer: a pilot study.

Journal: American journal of cancer research

Published: August 07, 2025

Combination of anti-epidermal growth factor receptor antibodies plus trifluridine-tipiracil as rechallenge strategy improves treatment outcomes in patients with RAS/BRAF wild-type refractory metastatic colorectal cancer.

Combination of anti-epidermal growth factor receptor antibodies plus trifluridine-tipiracil as rechallenge strategy improves treatment outcomes in patients with RAS/BRAF wild-type refractory metastatic colorectal cancer.

Journal: American journal of cancer research

Published: May 30, 2025

Diversified cell origin of Helicobacter pylori eradication-responsive gastric diffuse large B-cell lymphomas.

Diversified cell origin of Helicobacter pylori eradication-responsive gastric diffuse large B-cell lymphomas.

Journal: The Journal of pathology

Published: May 21, 2025

Metastatic Colon Cancer Recurring After Cetuximab Plus Doublet Chemotherapy Harboring Acquired KRAS G12C Mutant that Responded to Sotorasib Plus Cetuximab.

Metastatic Colon Cancer Recurring After Cetuximab Plus Doublet Chemotherapy Harboring Acquired KRAS G12C Mutant that Responded to Sotorasib Plus Cetuximab.

Journal: JCO precision oncology

Published: April 18, 2025

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 11, 2025

Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.

Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.

Journal: The Lancet. Oncology

Published: March 19, 2025

Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma.

Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: October 18, 2024

Multicenter Prospective First-Line Helicobacter Pylori Eradication for Localized Gastric "Pure" Diffuse Large B-Cell Lymphoma.

Multicenter Prospective First-Line Helicobacter Pylori Eradication for Localized Gastric "Pure" Diffuse Large B-Cell Lymphoma.

Journal: American journal of hematology

Published: October 10, 2024

Showing 1-12 of 94

Last Updated: 09/26/2026